19731-01-2

Basic information

• Product Name: Benzoic acid, 3-cyano-, hydrazide (9CI)
• Synonyms: Benzoic acid, 3-cyano-, hydrazide (9CI);3-cyanobenzohydrazide(SALTDATA: FREE)
• CAS NO: 19731-01-2
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.16068
• Product Categories: AMIDE
• Mol File: 19731-01-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.289g/cm³
• Refractive Index: 1.61
• Storage Temp.: 2-8°C
• PKA: 11.63±0.10(Predicted)
• CAS DataBase Reference: Benzoic acid, 3-cyano-, hydrazide (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-cyano-, hydrazide (9CI)(19731-01-2)
• EPA Substance Registry System: Benzoic acid, 3-cyano-, hydrazide (9CI)(19731-01-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 19731-01-2(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 3-cyano-, hydrazide (9CI) is a chemical compound with the molecular formula C8H7N3O. It is commonly used in the pharmaceutical and agricultural industries as a key intermediate in the synthesis of various compounds. It is also used as a building block for the production of dyes, rubber chemicals, and other organic compounds. Benzoic acid, 3-cyano-, hydrazide (9CI) has the potential to act as an antifungal and antibacterial agent, making it useful in the development of new drugs and agricultural products. Benzoic acid, 3-cyano-, hydrazide (9CI) is a versatile and valuable chemical that has a wide range of applications in different industries.

InChI:InChI=1/C8H7N3O/c9-5-6-2-1-3-7(4-6)8(12)11-10/h1-4H,10H2,(H,11,12)

Upstream product

• 13531-48-1 methyl 3-cyanobenzoate 
• 1711-11-1 3-cyanobenzoyl chloride 
• 2463-16-3 ethyl 3-cyanobenzoate 
• 1877-72-1 3-Cyanobenzoic acid 

Downstream Products

• 4291-06-9 3-(5-phenyl-[1,3,4]thiadiazol-2-yl)-benzonitrile 
• 161013-24-7 C₉H₅N₃OS 
• 1456613-80-1 3-(7-oxo-5-thioxo-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a][1,3,5]triazin-2-yl)benzonitrile 
• 1456614-08-6 C₁₃H₁₂N₆O₂S 
• 1016517-38-6 3-(5-amino-1H-1,2,4-triazol-3-yl)benzonitrile 

Relevant articles and documents

Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A2AReceptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents

Adenosine is an immunosuppressive factor in the tumor microenvironment mainly through activation of the A2A adenosine receptor (A2AR), which is a mechanism hijacked by tumors to escape immune surveillance. Small-molecule A2AR antagonists are being evaluat

Synthesis, characterization, and biological evaluation of new derivatives targeting MbtI as antitubercular agents

Tuberculosis (TB) causes millions of deaths every year, ranking as one of the most dangerous infectious diseases worldwide. Because several pathogenic strains of Mycobacterium tuberculosis (Mtb) have developed resistance against most of the established anti-TB drugs, new therapeutic options are urgently needed. An attractive target for the development of new antitubercular agents is the salicylate synthase MbtI, an essential enzyme for the mycobacterial siderophore biochemical machinery, absent in human cells. A set of analogues of I and II, two of the most potent MbtI inhibitors identified to date, was synthesized, characterized, and tested to elucidate the structural requirements for achieving an efficient MbtI inhibition and a potent antitubercular activity with this class of compounds. The structure-activity relationships (SAR) here discussed evidenced the importance of the furan as part of the pharmacophore and led to the preparation of six new compounds (IV-IX), which gave us the opportunity to examine a hitherto unexplored position of the phenyl ring. Among them emerged 5-(3-cyano-5-(trifluoromethyl)phenyl)furan-2-carboxylic acid (IV), endowed with comparable inhibitory properties to the previous leads, but a better antitubercular activity, which is a key issue in MbtI inhibitor research. Therefore, compound IV offers promising prospects for future studies on the development of novel agents against mycobacterial infections.

Novel Compounds

The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C- terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and cancer. Compounds of the invention include compounds having the formula (I): (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c, R1d, R1e, R1f, R1g, R2, X, L and A are as defined herein.